Market Closed -
OTC Markets
03:29:55 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.0625
USD
|
+5.93%
|
|
+13.64%
|
-10.33%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
32.67
|
30.93
|
1.294
|
1.607
|
0.8052
|
9.241
|
Enterprise Value (EV)
1 |
32.66
|
31
|
1.762
|
2.241
|
1.461
|
10.3
|
P/E ratio
|
-17.8
x
|
-15
x
|
-1.17
x
|
-0.41
x
|
0.25
x
|
-13.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
70.6
x
|
40.1
x
|
2.46
x
|
11.4
x
|
57
x
|
190
x
|
EV / Revenue
|
70.5
x
|
40.2
x
|
3.35
x
|
15.9
x
|
103
x
|
212
x
|
EV / EBITDA
|
-21.6
x
|
-18.9
x
|
-2.16
x
|
-5.2
x
|
-6.74
x
|
-11
x
|
EV / FCF
|
-93.9
x
|
-50.9
x
|
-5.33
x
|
0.6
x
|
-0.43
x
|
-8.71
x
|
FCF Yield
|
-1.06%
|
-1.97%
|
-18.8%
|
166%
|
-233%
|
-11.5%
|
Price to Book
|
-262
x
|
-148
x
|
-1.6
x
|
-0.33
x
|
-0.45
x
|
9.4
x
|
Nbr of stocks (in thousands)
|
46,018
|
51,633
|
36,981
|
48,733
|
53,683
|
256,695
|
Reference price
2 |
0.7100
|
0.5990
|
0.0350
|
0.0330
|
0.0150
|
0.0360
|
Announcement Date
|
8/10/18
|
7/1/19
|
8/10/20
|
9/28/21
|
7/15/22
|
6/20/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.4631
|
0.7706
|
0.5261
|
0.1409
|
0.0141
|
0.0485
|
EBITDA
1 |
-1.51
|
-1.64
|
-0.8166
|
-0.4307
|
-0.2168
|
-0.9346
|
EBIT
1 |
-1.533
|
-1.652
|
-0.8238
|
-0.4331
|
-0.2192
|
-0.9505
|
Operating Margin
|
-331.05%
|
-214.35%
|
-156.57%
|
-307.41%
|
-1,552.12%
|
-1,958.39%
|
Earnings before Tax (EBT)
1 |
-1.714
|
-2.215
|
-1.2
|
-4.383
|
3.173
|
-0.3793
|
Net income
1 |
-1.714
|
-2.215
|
-1.2
|
-4.383
|
3.173
|
-0.3793
|
Net margin
|
-370.03%
|
-287.47%
|
-228.07%
|
-3,110.8%
|
22,468.74%
|
-781.4%
|
EPS
2 |
-0.0400
|
-0.0400
|
-0.0300
|
-0.0800
|
0.0600
|
-0.002600
|
Free Cash Flow
1 |
-0.3478
|
-0.6096
|
-0.3305
|
3.715
|
-3.404
|
-1.183
|
FCF margin
|
-75.1%
|
-79.1%
|
-62.81%
|
2,636.28%
|
-24,105.44%
|
-2,436.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/10/18
|
7/1/19
|
8/10/20
|
9/28/21
|
7/15/22
|
6/20/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.08
|
0.47
|
0.63
|
0.66
|
1.06
|
Net Cash position
1 |
0.01
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.0459
x
|
-0.5731
x
|
-1.473
x
|
-3.024
x
|
-1.129
x
|
Free Cash Flow
1 |
-0.35
|
-0.61
|
-0.33
|
3.71
|
-3.4
|
-1.18
|
ROE (net income / shareholders' equity)
|
3,098%
|
1,356%
|
233%
|
150%
|
-92.9%
|
105%
|
ROA (Net income/ Total Assets)
|
-248%
|
-273%
|
-182%
|
-247%
|
-194%
|
-42.9%
|
Assets
1 |
0.691
|
0.8116
|
0.6591
|
1.774
|
-1.639
|
0.8839
|
Book Value Per Share
2 |
-0
|
-0
|
-0.0200
|
-0.1000
|
-0.0300
|
0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/10/18
|
7/1/19
|
8/10/20
|
9/28/21
|
7/15/22
|
6/20/23
|
|
1st Jan change
|
Capi.
|
---|
| -10.33% | 19.37M | | +25.83% | 661B | | +26.47% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +14.72% | 231B | | +5.26% | 200B | | -8.88% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|